Title Physician

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE)

NCT ID : 03697109
Phase : 3
Dr. Barkhoudarian

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

NCT ID : 03822117
Phase : 2
Dr. Kesari

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (AscenD-LB)

NCT ID : 04001517
Phase : 2
Dr. Kesari

A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer

NCT ID : 02589938
Phase : 3
Dr. Mena

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma

NCT ID : 01781468
Phase : 3
Dr. Sanghani

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

NCT ID : 03345095
Phase : 3
Dr. Kesari

Pemetrexed for the Treatment of Chordoma

NCT ID : 03955042
Phase : 1
Dr. Kesari

StimRouter™ for Pain Management in Post-stroke Shoulder Pain (PSSP)

NCT ID : 03093935
Protocol Number : STMR – PAIN 002 PSSP
Dr. Langevin

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

NCT ID : 03709888
Protocol Number : JWCI-17-0101
Dr. Kesari

Allogeneic Human Mesenchymal Stem Cells for Alzheimer’s Disease

NCT ID : 02833792
Protocol Number : STEM105-M-AD
Phase : 2
Dr. Kesari

Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial

NCT ID : 02873312
Protocol Number : CP-STMR-OAB-002
Dr. Langevin

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

NCT ID : 02847559
Protocol Number : NU 16C02
Phase : 2
Dr. Kesari

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

NCT ID : 03425292
Protocol Number : JWCI-17-0801
Dr. Kesari

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients (STELLAR)

NCT ID : 02796261
Protocol Number : OT-15-001 (20162068)
Phase : 3
Dr. Kesari

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

NCT ID : 03637764
Protocol Number : ACT15377
Phase : 1 and 2
Dr. Kesari

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

NCT ID : 02680795
Protocol Number : SPI-BEL-106
Phase : I
Dr. Kesari

Phase II Trial of AV-GBM-1 (Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens) as Adjunctive Therapy Following Primary Surgery plus Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma

NCT ID : 03400917
Protocol Number : CL-GBM-P01-US
Phase : II
Dr. Kesari

A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma

NCT ID : 03463265
Protocol Number : GBM-007
Phase : 2
Dr. Kesari

A Single-Center, Open-Label, Randomized, Phase II Study of NovoTTF-200A Alone and Combined with Temozolomide in Patients with Low-Grade Gliomas

NCT ID : 02507232
Protocol Number : JWCI-16-1101 (20162693)
Phase : II
Dr. Kesari

A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer

NCT ID : 02423525
Protocol Number : 1200-229 (20161975)
Phase : I
Dr. Kesari